Viral Vector & Plasmid DNA Manufacturing Market Research Report by Cell Line, Type, Transfection, Indication, Workflow, Application, End User, Country - North America Forecast to 2027 - Cumulative Impact of COVID-19

The North America Viral Vector & Plasmid DNA Manufacturing Market size was estimated at USD 216.14 million in 2021 and expected to reach USD 267.69 million in 2022, and is projected to grow at a CAGR 24.71% to reach USD 813.43 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Viral Vector & Plasmid DNA Manufacturing to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Cell Line, the market was studied across In-vitro and In-Vivo.

Based on Type, the market was studied across Adeno-Associated Virus, Adenovirus, Lentivirus, and Plasmid DNA.

Based on Transfection, the market was studied across Stable Transfection and Transient Transfection.

Based on Indication, the market was studied across Cancer, Genetic Disorder, and Infectious Disease.

Based on Workflow, the market was studied across Downstream Processing and Upstream Processing. The Downstream Processing is further studied across Fill-finish and Purification. The Upstream Processing is further studied across Vector Amplification & Expansion and Vector Recovery/Harvesting.

Based on Application, the market was studied across Antisense & RNAi, Cell Therapy, Gene Therapy, and Vaccinology.

Based on End User, the market was studied across Biotech Companies and Research Institutes.

Based on Country, the market was studied across Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Viral Vector & Plasmid DNA Manufacturing market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Viral Vector & Plasmid DNA Manufacturing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the North America Viral Vector & Plasmid DNA Manufacturing Market, including Advanced BioScience Laboratories, Inc., Batavia Biosciences B.V., Biovian Oy, Cevec Pharmaceuticals GmbH, Charles River Laboratories International, Inc., Creative Biogene, FinVector, FUJIFILM Diosynth Biotechnologies Inc., GE Healthcare, GeneOne Life Science, Inc., Genezen Laboratories, Inc., Kaneka Eurogentec S.A., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Sirion-Biotech GmbH, Spark Therapeutics, Inc., Thermo Fisher Scientific Inc., uniQure N.V., and Wuxi AppTec Co., Ltd..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the North America Viral Vector & Plasmid DNA Manufacturing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the North America Viral Vector & Plasmid DNA Manufacturing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the North America Viral Vector & Plasmid DNA Manufacturing Market?
4. What is the competitive strategic window for opportunities in the North America Viral Vector & Plasmid DNA Manufacturing Market?
5. What are the technology trends and regulatory frameworks in the North America Viral Vector & Plasmid DNA Manufacturing Market?
6. What is the market share of the leading vendors in the North America Viral Vector & Plasmid DNA Manufacturing Market?
7. What modes and strategic moves are considered suitable for entering the North America Viral Vector & Plasmid DNA Manufacturing Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Viral Vector & Plasmid DNA Manufacturing Market, by Cell Line
6.1. Introduction
6.2. In-vitro
6.3. In-Vivo

7. Viral Vector & Plasmid DNA Manufacturing Market, by Type
7.1. Introduction
7.2. Adeno-Associated Virus
7.3. Adenovirus
7.4. Lentivirus
7.5. Plasmid DNA

8. Viral Vector & Plasmid DNA Manufacturing Market, by Transfection
8.1. Introduction
8.2. Stable Transfection
8.3. Transient Transfection

9. Viral Vector & Plasmid DNA Manufacturing Market, by Indication
9.1. Introduction
9.2. Cancer
9.3. Genetic Disorder
9.4. Infectious Disease

10. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow
10.1. Introduction
10.2. Downstream Processing
10.3.1. Fill-finish
10.3.2. Purification
10.3. Upstream Processing
10.4.1. Vector Amplification & Expansion
10.4.2. Vector Recovery/Harvesting

11. Viral Vector & Plasmid DNA Manufacturing Market, by Application
11.1. Introduction
11.2. Antisense & RNAi
11.3. Cell Therapy
11.4. Gene Therapy
11.5. Vaccinology

12. Viral Vector & Plasmid DNA Manufacturing Market, by End User
12.1. Introduction
12.2. Biotech Companies
12.3. Research Institutes

13. Canada Viral Vector & Plasmid DNA Manufacturing Market
13.1. Introduction

14. Mexico Viral Vector & Plasmid DNA Manufacturing Market
14.1. Introduction

15. United States Viral Vector & Plasmid DNA Manufacturing Market
15.1. Introduction

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis, By Key Player
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. Advanced BioScience Laboratories, Inc.
17.1.1. Business Overview
17.1.2. Key Executives
17.1.3. Product & Services
17.2. Batavia Biosciences B.V.
17.2.1. Business Overview
17.2.2. Key Executives
17.2.3. Product & Services
17.3. Biovian Oy
17.3.1. Business Overview
17.3.2. Key Executives
17.3.3. Product & Services
17.4. Cevec Pharmaceuticals GmbH
17.4.1. Business Overview
17.4.2. Key Executives
17.4.3. Product & Services
17.5. Charles River Laboratories International, Inc.
17.5.1. Business Overview
17.5.2. Key Executives
17.5.3. Product & Services
17.6. Creative Biogene
17.6.1. Business Overview
17.6.2. Key Executives
17.6.3. Product & Services
17.7. FinVector
17.7.1. Business Overview
17.7.2. Key Executives
17.7.3. Product & Services
17.8. FUJIFILM Diosynth Biotechnologies Inc.
17.8.1. Business Overview
17.8.2. Key Executives
17.8.3. Product & Services
17.9. GE Healthcare
17.9.1. Business Overview
17.9.2. Key Executives
17.9.3. Product & Services
17.10. GeneOne Life Science, Inc.
17.10.1. Business Overview
17.10.2. Key Executives
17.10.3. Product & Services
17.11. Genezen Laboratories, Inc.
17.11.1. Business Overview
17.11.2. Key Executives
17.11.3. Product & Services
17.12. Kaneka Eurogentec S.A.
17.12.1. Business Overview
17.12.2. Key Executives
17.12.3. Product & Services
17.13. Lonza Group Ltd.
17.13.1. Business Overview
17.13.2. Key Executives
17.13.3. Product & Services
17.14. Merck KGaA
17.14.1. Business Overview
17.14.2. Key Executives
17.14.3. Product & Services
17.15. Miltenyi Biotec B.V. & Co. KG
17.15.1. Business Overview
17.15.2. Key Executives
17.15.3. Product & Services
17.16. Sirion-Biotech GmbH
17.16.1. Business Overview
17.16.2. Key Executives
17.16.3. Product & Services
17.17. Spark Therapeutics, Inc.
17.17.1. Business Overview
17.17.2. Key Executives
17.17.3. Product & Services
17.18. Thermo Fisher Scientific Inc.
17.18.1. Business Overview
17.18.2. Key Executives
17.18.3. Product & Services
17.19. uniQure N.V.
17.19.1. Business Overview
17.19.2. Key Executives
17.19.3. Product & Services
17.20. Wuxi AppTec Co., Ltd.
17.20.1. Business Overview
17.20.2. Key Executives
17.20.3. Product & Services

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing